Drug Profile
Research programme: P-selectin inhibitors - Pfizer
Alternative Names: PSI-290421; PSI-421; WAY-290421Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Cyclopropanes; Quinolines; Salicylic acids; Small molecules
- Mechanism of Action P selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in USA (PO)
- 19 Oct 2009 Wyeth has been acquired by Pfizer